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SYNTHESIS, BIOLOGICAL PROPERTIES AND ANTI-HIV-1 ACTIVITY
OF NEW PYRIMIDINE P1,P2-DINUCLEOTIDES
A. Miazga,1 P. Ziemkowski,1 M. A. Siwecka,1 A. Lipniacki,2 A. Piasek,2
and T. Kulikowski1
1Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warszawa, Poland
2Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
 New homo- and hetero-P1,P2-dinucleotides were prepared with the use of multistep procedures
starting from the monophosphates of 3′-fluoro-2-thiothymidine, 3′-fluoro-4-thiothymidine, AZT and
1-[(2-hydroxyethoxy)-methyl-5-propyl-6-phenylselenenyl]uracil. Anti-HIV properties of the synthe-
sized P1,P2-dinucleotides were evaluated against laboratory syncytia inducing strain HIV-1 in
CEM-T4 cells. Anti-HIV activities were in the range of 5–45 nM, and therapeutic indexes were
higher than 4666–14000. Interactions of the above mentioned compounds with recombinant HIV-1
reverse transcriptase were also investigated. The obtained results point to reverse transcriptase inhibi-
tion, with somewhat lower inhibitory activity than that of their parental nucleoside-5′-triphosphates.
Compound 6 may be regarded as a potent anti-HIV/AIDS drug.
KEYWORDS P1,P2-dinucleotides; anti-HIV agents; reverse transcriptase inhibitors
INTRODUCTION
It is known that 2′,3′-dideoxynucleoside analogues commonly used in
HIV/AIDS therapy are poorly phosphorylated to their active forms–5′-
triphosphates- in monocyte derived macrophages (MDM) and, therefore,
their therapeutic effects are limited. Direct introduction of nucleotides
into animal cells essentially does not occur. To overcome these limitations,
some 5′,5′-P1,P2 dinucleotides were previously synthesized; it was shown
that after encapsulation in erythrocytes (RBC) they protected in vitro
human macrophages from HIV-1 infection.[1] Such compounds are more
soluble in aqueous media than the parent nucleosides, and show better, as
compared with nucleosides, penetration into the cell in undegraded form.
5′,5′-P1,P2-dinucleotides undergo intracellular hydrolysis by dinucleotide
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pyrophosphatase to nucleoside 5′-monophosphates, which may be further
phosphorylated by kinases to 5′-triphosphates.[2]
Analogues of 3′-fluorothymidine thiated at the heterocyclic moiety are
selective inhibitors of HIV-1.[3] To enhance their solubility in water and
penetration into T- lymphocytes, we decided to synthesize thiated homo-
and hetero- 5′,5′-P1,P2-dinucleotides and investigate, without encapsulation
in RBC, their inhibitory activity toward HIV-1 in CEM-T4 cells.
RESULTS AND DISCUSSION
Chemistry
5′-Mononucleotides of 3′-azidothymidine and thiated analogues of 3′-
fluorothymidine were prepared from appropriate nucleosides in reaction
with POCl3, 1,2,4-triazole and triethylamine. 1-[(2-Hydroxyethoxy)methyl-
5-propyl-6- phenylselenenyl]uracil phosphate was synthesized with the use
of Yoshikawa procedure, employing direct phosphorylation with POCl3 in
trimethylphosphate.
P1,P2-homodinucleotides 3 and 4 were synthesized by condensation of 5′-
mononucleotides in the presence of tosyl chloride (Scheme 1). P1–3′-fluoro-
2-thiothymidine-P2–3′-azidothymidine pyrophosphate (6) was prepared with
the use of a multistep procedure, involving the conversion of 2′,3′-dideoxy-3′-
fluoro-2-thiothymidine 5′-mononucleotide to P1–3′-fluoro-2-thiothymidine-
5′-P2-diphenylpyrophosphate followed by condensation with AZTMP
(Scheme 2). 5′-Mononucleotide of 2′,3′-dideoxy-3′-fluoro-2-thiothymidine
was converted into morpholine derivative in reaction with morpholine
and 1,3-dicyclohexylcarbodiimide in t-BuOH/H2O. Coupling of 3′-fluoro-2-
thiothymidine 5′-monophosphate morpholidate with tri-n-butylammonium
salt of 1-[(2-hydroxyethoxy)methyl-5-propyl-6-phenylselenenyl]uracil phos-
phate led to heterodinucleotide 8 (Scheme 3).
PO
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R2
3: R1 = S; R2 = O 
4: R1 = O; R2 = S 
1: R1 = S, R2 = O
2: R1 = O, R2 = S
i
i: TsCl, DMAP, pyridine, RT, 24 h 
SCHEME 1 Synthesis of homodinucleotides (3, 4).
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SCHEME 2 Synthesis of P1–3′-fluoro-2-thiothymidine-P2–3′-azidothymidine pyrophosphate (6).
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i: morpholine, DCC, t-BuOH, 90oC, 3 h
ii: 1-[(2-hydroxyethoxy)methyl-5-propyl-6-phenylselenenyl]uracil phosphate, pyridine, RT, 18 h 
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7
8
SCHEME 3 Synthesis of P1–3′-fluoro-2-thiothymidine-P2–1-[(2-hydroxyethoxy)methyl-5-propyl-6-
phenylselenenyl]uracil pyrophosphate (8).
Biology
New P1,P2 dinucleotides 3, 4, and 6 cells exhibited potent antiviral activity
in CEM-T4 (ED50 15, 45, and 5 nM, respectively). Lower activity of 8 (ED50
200 nM) is most likely caused by larger nonpolar aryloseleno- substituent at
position 2 of uracil ring, while very high activity of compound 6 is probably
due to the presence of AZT as a part of the dinucleotide molecule.
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No cytotoxicity was observed in CEM-T4 cells at the highest tested con-
centration (100 µM), so that the therapeutic indexes were higher than
4,666–14,000.
To explain the mode of the antiviral action of the above mentioned thi-
ated P1,P2-pyrimidine analogues, corresponding nucleoside 5′-triphosphates
were synthesized, and their interactions with HIV-1 recombinant reverse
transcriptase (HIV-1 RT) were investigated and compared with those
of the P1,P2-dinucleotide analogues. The most active inhibitors were 5′-
triphosphates of 2′,3′-dideoxy-3′-fluoro-2-thiothymidine and 2′,3′-dideoxy-3′-
fluoro-4-thiothymidine, with inhibitory activity (IC50) 0.17 µM and 0.2 µM,
respectively, while the corresponding P1,P2-dinucleotides 3 and 4 exhibited
somewhat lower inhibitory activities (IC50 0.2 and 0.9 µM, respectively).
The obtained results show that antiviral activities of thiated pyrimidine
P1,P2-dinucleotides are only to some extent correlated with HIV RT inhi-
bition, and rather the 5′-triphosphates, resulting from the metabolism of
5′-monophosphates, are responsible for the antiviral activity.
EXPERIMENTAL
General Procedures
High resolution 1H NMR spectra were recorded on a Varian 500 MHz
in D2O, with DSS as internal standard. 31P NMR spectra were recorded on a
Varian 200 MHz in D2O, with 85% H3PO4 as external standard. Thin-layer
chromatography (TLC) was run on Merck silica gel F254 plates. The solvent
used for TLC was i-PrOH - conc. aq. NH3 -H2O 11:7:2. DEAE-Sephadex A-25
was purchased from Pharmacia. All other reagents, materials and solvents
were from Sigma-Aldrich (St. Louis, MO, USA).
Bis(2′,3′-dideoxy-3′-fluoro-2-thiothymidine)-5′,5′-P1,P2-pyrophosphate (3).
5′-Monophosphate of 2′,3′-dideoxy-3′-fluoro-2-thiothymidine (1) (51 mg,
0.14 mmol) was transformed into tri-n-butylammonium salt and dissolved
in 5 mL of dry DMF. To this solution was added 0.5 mL of dry pyridine,
catalytic amount of 4-dimethylaminopyridine and tosyl chloride (78 mg, 0.4
mmol). The solution was stirred at room temperature for 24 hours and 2
mL of water was added. After evaporation of the solvents the product was
purified by ion-exchange column chromatography with a DEAE-Sephadex
A-25 resign with a linear gradient (0–0.4 M) of aqueous triethylammonium
bicarbonate buffer as the mobile phase. The homogenous fractions con-
taining pure pyrophosphate were pooled and concentrated under reduced
pressure. The product was dissolved in a small amount of methanol and
solution of 100 mg NaI in 5 mL of acetone was added. The precipitated
sodium salt was filtered off, washed several times with acetone, and dried
over P2O5. Yield: 34.6 mg (70%); TLC Rf 0.72; 1H NMR (D2O) δ 7.87 (1H, d,
H6), 7.06 (1H, dd, H1′) 5.52–5.4 (1H, dd, H3′, J3′-F = 53.06 Hz), 4.55–4.49
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(1H, m, H4′, J4′-F = 27.03 Hz), 4.22 (2H, d, H5′, H5′′), 2.84–2.75 (1H, m,
H2′′), 2.33–2.19 (1H, m, H2′), 1.97 (3H, s, CH3); 31P NMR (D2O) δ -11.18;
MS m/z 661 (M-H)−.
Bis(2′,3′-dideoxy-3′-fluoro-4-thiothymidine)-5′,5′-P1,P2-pyrophosphate (4).
Compound received in the same manner as compound 3. Yield: 33 mg
(67%); TLC Rf 0.70; 1H NMR (D2O) δ 7.77 (1H, d, H6), 6.37 (1H, dd, H1′),
5.51–5.39 (1H, dd, H3′, J3′-F = 52.56 Hz), 4.52–4.47 (1H, m, H4′, J4′-F = 27.53
Hz), 4.18 (2H, d, H5′, H5′′), 2.67–2.59 (1H, m, H2′′), 2.45–2.32 (1H, m,
H2′), 2.05 (3H, s, CH3); 31P NMR (D2O) δ −11.15; MS m/z 661 (M-H)−.
P1-(2′,3′-dideoxy-3′-azidothymidine)-P2-(2′,3′-dideoxy-3′-fluoro-2-thiothy
midine) pyrophosphate (6). Compound 1 (68 mg, 0.2 mmol) was con-
verted into tri-n-butylammonium salt (free acid was dissolved in 3 mL of
methanol with 0.4 mL tri-n-butylamine and stirred for 30 minutes) and
dissolved in the mixture of dry 1,4-dioxane (1 mL) and DMF (0.25 mL).
Diphenyl chlorophosphate (42 µL, 0.2 mmol) and tri-n-butylamine (55 µL,
0.23 mmol) was added and stirred in room temperature for 3 hours.
After evaporation of the solvents diethyl ether (10 mL) was added, and
the reaction mixture was left standing for 1 hour in refrigerator. Diethyl
ether was decanted, and the traces of ether were removed by evaporation
with dioxane. Resulting P1-nucleoside-5′-P2-diphenylpyrophosphate 5 was
dissolved in 1 mL of dry pyridine and triethylammonium salt of 3′-azido-2′,3′-
dideoxytymidine 5′-monophosphate (69.4 mg, 0.2 mmol) was added and
stirred in room temperature for 18 hours. Reaction mixture was evaporated
to dryness under reduced pressure and extracted two times with diethyl
ether. The residue was purified by ion-exchange column chromatography
with a DEAE-Sephadex A-25 resign with a linear gradient (0–0.4 M) of
aqueous triethylammonium bicarbonate buffer as the mobile phase. The
fractions containing pure pyrophosphate were pooled and concentrated
under reduced pressure and converted to sodium salt. Yield: 17.3 mg (12%);
TLC Rf 0.67; 1H NMR (D2O) δ 7.88 (1H, d, H6), 7.64 (1H, s, H6AZT), 7.05
(1H, dd, H1′) 6.18 (1H, t, H1′AZT), 5.50–5.39 (1H, dd, H3′, J3′-F = 52.73
Hz), 4.54–4.47 (2H, m, H4′, H3′AZT), 4.22–4.10 (5H, m, H5′, H5′′, H4′AZT),
2.82–2.73 (1H, m, H2′′), 2.44 (2H, m, H2′AZT, H2′′AZT), 2.32–2.17 (1H, m,
H2′), 1.95 i 1.89 (6H, 2 s, 2 CH3); 31P NMR (D2O) δ −11.21, −11.07; MS
m/z 668 (M-H)−.
P1-(1-[(2-hydroxyethoxy)methyl]-6-phenylselenenyl-5-propyluracil)-P2-(2′,
3′-dideoxy-3′-fluoro-2-thiothymidine) pyrophosphate (8). To the solution
of 1 (44.2 mg, 0.13 mmol) in 2 mL of water tert-butanol (2 mL) and mor-
pholine (45 µL, 0.52 mmol) were added, and reaction mixture was heated
at 90◦C. 1,3-Dicyclohexylcarbodiimide (107.5 mg, 0.52 mmol) in 3 mL of
tert-butanol was added and the reaction mixture was stirred and heated at
90◦C for 3 hours. After this time 2 mL of water was added and the mixture
was extracted with diethyl ether (3 × 10 mL). The combined organic
fractions were dried over Na2SO4 and evaporated under reduced pressure
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to syrup. Received morpholine derivative of o-P1-nucleosidephosphate 7
was dissolved in 1 mL of anhydrous pyridine, and tri-n-butylammonium
salt of 1-[(2-hydroxyethoxy)methyl]-6-phenylselenenyl-5-propyluracil 5′-
monophosphate (50 mg, 0.11 mmol) was added. The mixture was stirred
at room temperature for 18 hours. After evaporation of the solvents the
residue was extracted two times with diethyl ether. The residue was purified
by ion-exchange column chromatography with a DEAE-Sephadex A-25
resign with a linear gradient (0–0.4 M) of aqueous triethylammonium
bicarbonate buffer as the mobile phase. The fractions containing pure
pyrophosphate were pooled and concentrated under reduced pressure and
converted to sodium salt. Yield: 13.5 mg (15%); TLC Rf 0.7; 1H NMR (D2O)
δ 7.90 (1H, d, H6), 7.45–7.33 (5H, m, Ph), 7.04 (1H, dd, H1′), 5.60 (2H, s,
OCH2N), 5.52–5.41 (1H, dd, H3′), 4.56–4.51 (1H, m, H4′), 4.27–4.2 (2H,
m, H5′, H5′′), 3.96–3.74 (4H, m, CH2CH2), 2.83–2.74 (1H, m, H2′′), 2.52
(2H, m, CH2CH2CH3), 2.29–2.15 (1H, m, H2′), 1.95 (3H, s, CH3), 1.18
(2H, m, CH2CH2CH3)0.79 (3H, t, CH2CH2CH3); 31P NMR (D2O) δ −11.27,
−10.57; MS m/z 784 (M-H)−.
Inhibition of HIV-1 Virus Replication
Antiviral activity was determined as follows: CEM-T4 cells (kindly pro-
vided by NIH AIDS Research and Reference Program) inoculated with HIV-1
(syncytia inducing phenotype) were cultured for up to 10 days in 96 well cul-
ture plate with various concentrations of the tested compounds in triplicate.
The media over the cell cultures were collected at various time intervals, and
the amounts of p24 protein were determined. The efficacy of inhibition of
HIV-1 replication by the tested compounds was compared and related to the
control culture grown in standard medium, as well as to cells cultured in
media enriched with known amounts of AZT.
The cytotoxicity of the investigated compounds was tested in CEM-T4
cells. After 10 days of culture at various concentrations of the tested com-
pounds, the cell viability was determined by the standard MTT method.
HIV-1 Reverse Transcriptase Assay
The activity of HIV-1 RT was determined using a colorimetric method in-
volving incorporation of digoxigenin- and biotin-labeled dUTP into DNA[4].
Standard reaction mixture contained 46 mM Tris-HCl (pH 7.8), 9.2 mM
DTT, 27.5 mM MgCl2, 266 mM KCl, 0.05% Triton X-100, 1.25 mg/m BSA,
0.075 mM EDTA, 0.1 mM poly(A)oligo(dT)15, digoxigenin- and biotin-
labeled nucleotides dUTP/dTTP (10µM), 3 µL RT (30 mU/µL), and 20 µL
(0.01–5 µM) of inhibitor solution. The mixture was incubated at 37◦C for 1
hour, and unreacted substrates were washed out. Antibodies against digoxi-
genin (200 µL) conjugated with peroxidase (200 mU/mL) were added and
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incubated at 37◦C for 1 hour. Antibodies were washed out, and 200 µL of
2,2′-azino-di(3-ethylbenzothiazoline) was added, left for 30 minutes at room
temperature, and absorbance at 405 nm was measured with the use of ELISA
microtiter plate reader.
CONCLUSION
Among the above mentioned P1,P2-dinucleotides, compound 6 is the
most potent and selective anti HIV-1 agent, in which the influence of the
3′-azido-substituent is clearly visible. It may be regarded as a potential anti-
HIV/AIDS drug.
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